DNTHNasdaqPharmaceutical PreparationsFiscal year ends December 31

Dianthus Therapeutics, Inc. /DE/

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026

$74.54+2.45 (+3.40%)

Close on Oct 19, 2026

Market cap: $4.18B
P/E (TTM): –
Dividend yield: 0.00%

Dianthus Therapeutics, Inc. /DE/ income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31
Revenue	2.04	6.24	2.83	–	–	–	0	0	0	0
Research & Development	146	83	33	29	47	51	59	41	28	5.78
General & Administrative	34	25	18	6.74	28	28	24	19	7.83	3.49
Operating Expenses	180	108	51	36	75	79	83	60	36	9.27
Operating Income	-178	-102	-48	-30	-75	-79	-83	-60	-36	-9.27
Interest Expense	–	–	–	–	–	–	–	–	–	0.16
Interest & Investment Income	9.96	11	3.34	1.15	–	–	–	–	–	–
Other Non-Operating Income	16	17	4.62	1.23	–	–	–	2.45	0.24	-0.16
Asset Impairment Charges	–	–	–	0	0	0	0	0	0	0
Gain (Loss) on Sale of Assets	–	–	–	0	-0.10	0.00	–	-0.07	–	–
Income Tax Expense	0	0	0	0	0	0	0	0	0	0
Net Income incl. Noncontrolling Interests	-162	-85	-44	-28	-71	-75	-77	-58	-35	-9.43
Net Income	-162	-85	-44	-28	-71	-75	-77	-58	-35	-9.43
Net Income to Common	–	–	–	–	–	–	-77	-58	-36	-9.74
EPS (Basic)(per share)	-4.20	-2.55	-8.45	-32.57	-86.43	-114.57	-138.69	-209.71	-1,281.04	-4,365.05
EPS (Diluted)(per share)	-4.20	-2.55	-8.45	-32.57	-86.43	-114.57	-138.69	-209.71	-1,281.04	-4,365.05
Shares Outstanding (Basic, Weighted)(shares)	39	33	5.15	0.87	0.82	0.66	0.55	0.27	0.03	0.00
Shares Outstanding (Diluted, Weighted)(shares)	39	33	5.15	0.87	0.82	0.66	0.55	0.27	0.03	0.00
Dividend per Share(per share)	0.00	0.00	0.00	–	–	–	–	–	–	–
EBITDA	–	–	–	-28	-73	-77	-81	-59	-35	-9.26

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin: –
Operating margin: -10699.6%
Net margin: -9442.3%
Return on equity, FY2025: -38.4%

Financial strength

Current ratio: 26.10
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 321.5%

Valuation

P/E ratio: –
Price to sales: 2051.28
Price to book: 3.56
Dividend yield: 0.00%